fda warning letter hims compounded semaglutide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Hims & Hers' Super Bowl

As such, the Stanford University School of Medicine Institutional Review Board determined that the study was exempt from review (IRB exemption granted

Rakhit et al., 2004)

Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, et al

Researchers ordering CJC-1295 Ipamorelin blend Canada receive a dual-peptide formulation with verified purity

Rare but Serious Causes Including Malignancies In some cases, black stools can be a sign of a serious condition like cancer

However, people with MS who also have obesity or type 2 diabetes may be candidates for GLP-1 therapy, says Alan David Kaye, MD, PhD, a professor and the vice chair of research in the anesthesiology department at LSU Health in Shreveport, Louisiana